A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1) — Stella
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(5 sites)
United States
UCHealth Sue Anschutz-Rodgers Eye Center,, Aurora, Colorado
Bascom Palmer Eye Institute, Miami, Florida
Massachusetts Eye and Ear Infirmary, Boston, Massachusetts
Oregon Health & Science University, Portland, Oregon